KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Shares Outstanding (Weighted Average) (2023 - 2025)

Biocryst Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 9 years, with the latest figure at $209.9 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 1.55% year-over-year to $209.9 million; the TTM value through Dec 2025 reached $209.9 million, up 1.55%, while the annual FY2025 figure was $209.9 million, 1.55% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $209.9 million in Q4 2025 per BCRX's latest filing, roughly flat from $209.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $209.9 million in Q4 2025 to a low of $188.5 million in Q1 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $201.9 million, with a median of $206.6 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 9.42% in 2024, then increased 1.27% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $192.2 million in 2023, then rose by 7.54% to $206.7 million in 2024, then grew by 1.55% to $209.9 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Shares Outstanding (Weighted Average) are $209.9 million (Q4 2025), $209.5 million (Q3 2025), and $209.5 million (Q2 2025).